A Trial of Neoadjuvant TS-1 and Cisplatin for Type 4 and Large Type 3 Gastric Cancer
Gastric Neoplasm
About this trial
This is an interventional treatment trial for Gastric Neoplasm focused on measuring Neoadjuvant Therapy, Stomach Neoplasms, Cisplatin, S-1(combination)
Eligibility Criteria
Inclusion Criteria: histologically proven adenocarcinoma of stomach Borrmann type 4 or large (>=8 cm) type 3 no evidence of distant metastasis including liver(M0) no evidence of para-aortic and/or retropancreatic lymph node metastasis(N0-2) no peritoneal metastasis and negative peritoneal lavage cytology (PLS) with laparoscopic confirmation no involvement of the esophagus with > 3cm an age of 20-75 years an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 no prior chemotherapy, radiotherapy for any malignancy no prior surgery for gastric cancer except for endoscopic membrane resection (EMR) no breeding from primary tumor or gastrointestinal stenosis sufficient oral intake adequate organ function written informed consent Exclusion Criteria: synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ pregnant or breast-feeding women severe mental disease systemic administration of corticosteroids, flucytosine, phenytoin or warfarin other severe complications such as paralytic ileus, intestinal pneumonitis, pulmonary fibrosis, or ischemic heart disease myocardial infarction within six disease-free months
Sites / Locations
- Aichi Cancer Center Hospital
- Fujita Health University
- National Cancer Center Hospital East
- National Hospital Organization Shikoku Cancer Center
- Gifu Municipal Hospital
- Hiroshima City Hospital
- Itami City Hospital
- Iwate Medical University
- Kagoshima University,Faculty of Medicine
- Kanagawa Cancer Center
- Kyoto Second Red Cross Hospital
- Miyagi Cancer Center
- National Hospital Organization, Sendai Medical Center
- Nagaoka Chuo General Hospital
- Niigata Cancer Center Hospital
- Tsubame Rosai Hospital
- Oita University Fuculty of Medicine
- Osaka National Hospital
- Osaka Medical Center for Cancer and Cardiovascular Diseases
- Kinki University School of Medicine
- Sakai Municipal Hospital
- Osaka Medical College
- Toyonaka Municipal Hospital
- Saitama Cancer Center
- National Defense Medical College
- Shizuoka General Hospital
- Tokyo Metropolitan Komagome Hospital
- Tokyo Medical and Dental University Hospital
- National Cancer Center Hospital
- Cancer Institute Hospital
- International Medical Center of Japan
- Tokyo Metropolitan Bokutoh Hospital
- Toyama Prefectural Central Hospital
- Wakayama Medical University, School of Medicine
- Yamagata Prefectural Central Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
1
2
Procedure/Surgery: Gastrectomy with more than D2 dissection
Drug: Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy